Type III Interferon (IFN) Induces a Type I IFN-like Response in a Restricted Subset of Cells Through Signaling Pathways Involving Both the Jak-STAT Pathway and the Mitogen-activated Protein Kinases

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2007 May 18

PMID 17507495

Citations 246

Authors

Zhangle Zhou

Ole J Hamming

Nina Ank

Soren R Paludan

Anders L Nielsen

Rune Hartmann

Affiliations

Soon will be listed here.

Abstract

Type III interferon (IFN) is a novel member of the interferon family. Type III IFN utilizes a receptor complex different from that of type I IFN, but both types of IFN induce STAT1, STAT2, and STAT3 activation. Here we describe a detailed comparison of signal transduction initiated by type I and type III IFN. Gene expression array analysis showed that IFN types I and III induced a similar subset of genes. In particular, no genes were induced uniquely by type III IFN. Next, we used chromatin immunoprecipitation (ChIP) analysis to investigate the promoter activation by types I and III IFN. The ChIP assays demonstrated that stimulation of cells with both type I and type III IFN resulted in the recruitment of ISGF3 transcription factor components to the promoter region of responsive genes and in an increase of polymerase II loading and histone acetylation. Whereas IFN type I signaling was observed for a broad spectrum of cell lines, type III IFN signaling was more restricted. The lack of IFN type III signaling was correlated with a low expression of the IL28Ra component of the IFN type III receptor, and IL28Ra overexpression was sufficient to restore IFN type III signaling. We also tested the activation of mitogen-activated protein (MAP) kinases by type III IFN and found that type III IFN relies strongly upon both p38 and JNK MAP kinases for gene induction.

Citing Articles

Expression and function of interferon lambda receptor 1 variants.

Novotny L, Meissner E FEBS Lett. 2024; 599(4):466-475.

PMID: 39435588 PMC: 11850208. DOI: 10.1002/1873-3468.15041.

Suppression of Interferon Response and Antiviral Strategies of Bunyaviruses.

He Y, Shen M, Wang X, Yin A, Liu B, Zhu J Trop Med Infect Dis. 2024; 9(9).

PMID: 39330894 PMC: 11435552. DOI: 10.3390/tropicalmed9090205.

Crucial Roles of RSAD2/viperin in Immunomodulation, Mitochondrial Metabolism and Autoimmune Diseases.

Chen S, Ye J, Lin Y, Chen W, Huang S, Yang Q Inflammation. 2024; .

PMID: 38909344 DOI: 10.1007/s10753-024-02076-5.

Interferon signaling in the nasal epithelium distinguishes among lethal and common cold coronaviruses and mediates viral clearance.

Otter C, Renner D, Fausto A, Tan L, Cohen N, Weiss S Proc Natl Acad Sci U S A. 2024; 121(21):e2402540121.

PMID: 38758698 PMC: 11127059. DOI: 10.1073/pnas.2402540121.

Structure-function of type I and III interferons.

de Weerd N, Kurowska A, Mendoza J, Schreiber G Curr Opin Immunol. 2024; 86:102413.

PMID: 38608537 PMC: 11057355. DOI: 10.1016/j.coi.2024.102413.

References

Uddin S, Majchrzak B, Woodson J, Arunkumar P, AlSayed Y, Pine R . Activation of the p38 mitogen-activated protein kinase by type I interferons. J Biol Chem. 1999; 274(42):30127-31. DOI: 10.1074/jbc.274.42.30127. View

Caraglia M, Abbruzzese A, Leardi A, Pepe S, Budillon A, Baldassare G . Interferon-alpha induces apoptosis in human KB cells through a stress-dependent mitogen activated protein kinase pathway that is antagonized by epidermal growth factor. Cell Death Differ. 1999; 6(8):773-80. DOI: 10.1038/sj.cdd.4400550. View

Robek M, Boyd B, Chisari F . Lambda interferon inhibits hepatitis B and C virus replication. J Virol. 2005; 79(6):3851-4. PMC: 1075734. DOI: 10.1128/JVI.79.6.3851-3854.2005. View

Ida-Hosonuma M, Iwasaki T, Yoshikawa T, Nagata N, Sato Y, Sata T . The alpha/beta interferon response controls tissue tropism and pathogenicity of poliovirus. J Virol. 2005; 79(7):4460-9. PMC: 1061561. DOI: 10.1128/JVI.79.7.4460-4469.2005. View

Platanias L . Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005; 5(5):375-86. DOI: 10.1038/nri1604. View

Meager A, Visvalingam K, Dilger P, Bryan D, Wadhwa M . Biological activity of interleukins-28 and -29: comparison with type I interferons. Cytokine. 2005; 31(2):109-18. DOI: 10.1016/j.cyto.2005.04.003. View

Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst S, Otte J . IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am J Physiol Gastrointest Liver Physiol. 2005; 289(5):G960-8. DOI: 10.1152/ajpgi.00126.2005. View

Nowak D, Tian B, Brasier A . Two-step cross-linking method for identification of NF-kappaB gene network by chromatin immunoprecipitation. Biotechniques. 2005; 39(5):715-25. DOI: 10.2144/000112014. View

Stetson D, Medzhitov R . Recognition of cytosolic DNA activates an IRF3-dependent innate immune response. Immunity. 2006; 24(1):93-103. DOI: 10.1016/j.immuni.2005.12.003. View

10.

Ank N, West H, Bartholdy C, Eriksson K, Thomsen A, Paludan S . Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol. 2006; 80(9):4501-9. PMC: 1472004. DOI: 10.1128/JVI.80.9.4501-4509.2006. View

11.

Lasfar A, Lewis-Antes A, Smirnov S, Anantha S, Abushahba W, Tian B . Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma. Cancer Res. 2006; 66(8):4468-77. DOI: 10.1158/0008-5472.CAN-05-3653. View

12.

Sato A, Ohtsuki M, Hata M, Kobayashi E, Murakami T . Antitumor activity of IFN-lambda in murine tumor models. J Immunol. 2006; 176(12):7686-94. DOI: 10.4049/jimmunol.176.12.7686. View

13.

Doyle S, Schreckhise H, Khuu-Duong K, Henderson K, Rosler R, Storey H . Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology. 2006; 44(4):896-906. DOI: 10.1002/hep.21312. View

14.

Marcello T, Grakoui A, Barba-Spaeth G, Machlin E, Kotenko S, MacDonald M . Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology. 2006; 131(6):1887-98. DOI: 10.1053/j.gastro.2006.09.052. View

15.

Nguyen V, Chen J, Hong F, Ishac E, Gao B . Interferons activate the p42/44 mitogen-activated protein kinase and JAK-STAT (Janus kinase-signal transducer and activator transcription factor) signalling pathways in hepatocytes: differential regulation by acute ethanol via a protein kinase.... Biochem J. 2000; 349(Pt 2):427-34. PMC: 1221165. DOI: 10.1042/0264-6021:3490427. View

16.

Verma A, Deb D, Sassano A, Uddin S, Varga J, Wickrema A . Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I interferons and transforming growth factor-beta on normal hematopoiesis. J Biol Chem. 2002; 277(10):7726-35. DOI: 10.1074/jbc.M106640200. View

17.

Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore T . IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol. 2002; 4(1):63-8. DOI: 10.1038/ni873. View

18.

Kotenko S, Gallagher G, Baurin V, Lewis-Antes A, Shen M, Shah N . IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. 2002; 4(1):69-77. DOI: 10.1038/ni875. View

19.

Saeed A, Sharov V, White J, Li J, Liang W, Bhagabati N . TM4: a free, open-source system for microarray data management and analysis. Biotechniques. 2003; 34(2):374-8. DOI: 10.2144/03342mt01. View

20.

Li Y, Sassano A, Majchrzak B, Deb D, Levy D, Gaestel M . Role of p38alpha Map kinase in Type I interferon signaling. J Biol Chem. 2003; 279(2):970-9. DOI: 10.1074/jbc.M309927200. View